Phase 1 study of DNL201 in healthy volunteer.
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2017
At a glance
- Drugs DNL-201 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Denali Therapeutics Inc
- 26 Dec 2017 New trial record
- 20 Dec 2017 Status changed from suspended to recruiting, as reported in a Denali Therapeutics Inc Media Release.
- 20 Dec 2017 Based on a full review of data from this study and additional preclinical data, the FDA has removed the previously imposed partial clinical hold, as reported in a Denali Therapeutics Inc Media Release.